tbuckley/cabot-search huggingface dataset:
The Influence of Syphilis upon the Course of Other Diseases
Authors: James S. Mclester
Journal: Annals of Internal Medicine (1928)

Article1 October 1928The Influence of Syphilis upon the Course of Other DiseasesJAMES S. MCLESTERJAMES S. MCLESTERSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-2-4-348 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe tendency of Syphilis to pro duce vague clinical pictures, difficult of recognition, was to the preceding generation of physicians proverbial. Today, however, much of the obscurity which formerly shrouded the manifestations of this disease has been cleared up by the routine use of the Wassermann test, and because of the resulting ease of recognition in its commoner forms, syphilis is no longer looked upon as a potent cause of obscure illness. This change of attitude is not, I submit, entirely justified, as is evidenced, I believe, by clinical experience as well as the well known fact that syphilis, especially... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Birmingham, Alabama*Read before the American College of Physicians, March 6, 1928, New Orleans, La. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1928Volume 2, Issue 4Page: 348-351KeywordsSyphilis ePublished: 1 December 2008 Issue Published: 1 October 1928 PDF downloadLoading ...
Combination of non-cytotoxic agents with anti-angiogenic activity for metronomic therapy of solid tumors: A Phase II study
Authors: Giuseppe Curigliano, Cristina Noberasco, Francesco Bertolini, Alessandra Milani, Sara Manzoni, Lucia Dodaro, Andrea Rocca, Filippo De Braud
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

4583 

Successful cancer therapies targeting the tumor vasculature would be expected to block the existing blood supply and to prevent tumor neovascularization. To evaluate safety and toxicity of metronomic long term administration of alpha interferon (IFNα), thalidomide and celecoxib we designed a randomized, open label phase II clinical trial. Patients with proven metastatic solid tumors with a slow rate of growth, defined as free interval from treatment to progression > of 6 months, were considered suitable for the study. From January 2002 to November 2003 we randomized 34 patients to 6 groups: A1. IFNα + thalidomide (5 patients), A2. IFNα + thalidomide + celecoxib (6 patients). B1. IFNα + celecoxib (6 patients), B2. IFNα + celecoxib + thalidomide (5 patients). C1. celecoxib + thalidomide (6 patients). C2. celecoxib + thalidomide + IFNα (6 patients). Treatment plan included daily administration of subcutaneous alpha-interferon 0.5 MU/12 hrs, thalidomide 100 mg/daily orally, celecoxib 200 mg/12 hrs orally for at least 4 months even in presence of progressive disease. Patients included in drugs arm A2, B2 and C2 started with 2 drugs for 2 months and than added the third drug to combination, continuing therapy for two additional months. Thirteen patients had renal cell carcinoma, 9 had hepatocellular carcinoma, and 12 had other tumors ( 4 medullary thyroid carcinoma,1 follicular thyroid carcinoma, 3 prostatic cancer, 2 unknown primary tumor, 2 neuroendocrine tumors). After 4 months of treatment, among 30 patients evaluable for response, we observed 1 partial response (3%) 20 stable disease (67%). 47% of patients had clinical benefit (partial response + stable disease lasting more than 6 months ). No grade IV toxicity has been observed according to NCI criteria. Grade III common adverse events included leucopenia (7%); anemia (3%); asthenia (7%), and lethargy (7%). We observed skin toxicity scored as grade I in 17% and grade II in 20% limited to the patients treated with celecoxib. Circulating endothelial cells (CEC) and progenitors (CEP) were measured by flow cytometry before therapy and every two months thereafter. Patients with long lasting stable disease had a significant decrease in CEC and CEP counts. An increase in apoptotic CEC was observed in the patient who achieved a partial response in lung metastasis from renal cells carcinoma, treated with celecoxib plus thalidomide (arm C1). These promising data suggest that metronomic, long term administration of IFNα + celecoxib + thalidomide different combination schedules can be considered a safe and active antitumor treatment. CEC could be considered as surrogate marker of antiangiogenic activity. This study is supported by AIRC
Abstract 5323: Expression of Calsequestrin D307H Mutant Protein Partially Rescues the Abnormal Calcium Handling and Ultra Structural Defects of CASQ2 Null Hearts
Authors: Anuradha Kalyanasundaram, Serge Viatchenko-Karpinski, Veronique Lacombe, Clara Franzini-Armstrong, Sandor Györke, Bjorn C Knollmann, Muthu Periasamy
Journal: Circulation (2008)

Calsequestrin (CASQ2) is the major calcium binding protein located in the cardiac junctional sarcoplasmic reticulum (jSR). Several mutations have been reported in human CASQ2 and have been linked to Catecholamine induced Polymorphic Ventricular Tachycardia (CPVT). To understand how a point mutation CASQ2 D307H that changes the negative aspartate (D) to a positive histidine (H), causes ventricular tachycardia, we generated a mouse model that expresses the D307H mutant protein in a CASQ2 null background (CASQ2 −/− mice). Our results demonstrate that the mutant protein can be stably expressed, properly targeted and localized to the jSR. This refutes a recently reported study that suggested a highly unstable, easily degraded CASQ2 D307H mutant protein (J Clin Invest. 2007, 117(7):1814–23). Expression of the mutant CASQ2 D307H protein did not affect RyR2, DHPR, SERCA2a and calreticulin levels, but significantly restored both triadin and junctin from the very low levels in the CASQ2 −/− mouse. Expression and appropriate targeting of CASQ2 D307H was directly confirmed by electron microscopy: the “tightly” packed arrangement of CASQ2 within the jSR, which was completely missing in CASQ2 −/− mouse myocardium, was restored. This requires both the presence of CASQ2 and its interaction with triadin/junctin. Calcium transients and calcium load in ventricular myocytes isolated from CASQ2 D307H hearts were not significantly different from those of WT cells. Standard beta-adrenergic stimulation protocols did not induce spontaneous calcium releases and triggered beats in isolated CASQ2 D307H myocytes. Studies are in progress using telemetry to examine if the D307H mice in the null background develop VT upon exercise, a hallmark of CPVT linked mutations. Our studies thus far suggest that mutant CASQ2 D307H protein is capable of interacting with either triadin or junctin, or both, allowing it to be localized within the jSR. In conclusion, our data demonstrate that altered protein stability of CASQ2 D307H is not the causative mechanism for the CPVT phenotype. Other mechanisms such as altered interaction between jSR proteins, decreased SR buffering and/or altered regulation of the RyR2 channels by mutant CASQ2 D307H should be explored. This research has received full or partial funding support from the American Heart Association, AHA Great Rivers Affiliate (Delaware, Kentucky, Ohio, Pennsylvania &amp; West Virginia).
Obstructive sleep apnea contributes acutely to left ventricular dysfunction independently of hypoxaemia
Authors: Katerina Vlami, George Matziaras, Anastasia Papastefanou, Argiro Antaraki, Nikos Kostomitsopoulos, Vaggelis Balafas, Alkiviadis Kostakis, Spiros Papiris
Journal: European Respiratory Journal (2011)

Background: Obstructive sleep apnea has detrimental effects on function of left ventricle. It is also known that large decreases in intrathoracic pressure occur during obstructive apnoeas.

The aim of this study was to determine the acute changes in left sided heart function that occur in response to the decreased intrathoracic pressure in an obstructive sleep apnea model in rats under condition of normoxia.

Methods: Experiments were conducted in ten male adult Wistar rats weighing 350 gr, which were anaesthetized with Ketamine-Xylazine intraperitoneally. Animals were breathing after being tracheostomized and connected in a circuit with an electromagnetic valve which was closing periodically mimicking obstructive apnoeas.Arterial saturation was at SaO2:97% constantly. End Diastole Volume (EDV), Stroke Volume (SV) and Ejection Fraction (EF%) of left ventricle were measured with an anatomical M-mode echocardiographic method. Data analyzed and compared between quite breathing (time 0) and breathing after two hours of airway obstructions (time 0+2).

Results: The cardiac measurements were compared using the Wilcoxon signed-rank test. EDV and SV were statistically significant reduced (p<0.05) between time 0 and time 0+2. EF was reduced but not statistically significant at the same time period.

Conclusions: In this study our findings suggest that left ventricular function is affected acutely with reduction of EDV and SV after two hours of airway obstructions independently of hypoxaemia. These results suggest that in obstructive sleep apnea, negative intrathoracic pressure which occurs during apnea may contribute to changes in myocardial mechanics.
Abstract 12567: Pooled Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol After Percutaneous Coronary Intervention
Authors: Jae-Sik Jang, Sang-Ryul Chung, Han-Young Jin, Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Bomin Park, Ki-Hun Kim, Dong-Kie Kim, Sang-Hoon Seol, Doo-Il Kim, Kyoung-Im Cho, Bo-Hyun Kim, Yong-Hyun Park, Hyoung-Gon Je, Dong-Soo Kim
Journal: Circulation (2011)

Background: Cilostazol has reduced restenosis and repeat revascularization in patients undergoing percutaneous coronary intervention (PCI). The objective of this study was to evaluate the impact of cilostazol on the angiographic and clinical outcomes in patients undergoing PCI with bare-metal stents (BMS) or drug-eluting stents (DES) and treated with aspirin and thienopyridine.

Methods: We searched MEDLINE, EMBASE, Cochrane databases, and conference proceedings for RCTs comparing triple antiplatelet therapy (aspirin, thienopyridine and cilostazol) with standard dual antiplatelet therapy. Pooled weighted mean difference (WMD) and pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated.

Results: A total of 11 RCTs including 5,176 patients with a median follow-up period of 6-9 months were included in the analysis. Pooled analysis showed that cilostazol was associated with a significant reduction in late loss (WMD 0.16, 95% CI 0.12-0.20, p<0.001) and angiographic restenosis (OR 0.51, 95% CI 0.41-0.65, p<0.001) for both DES and BMS and also individually. Triple antiplatelet therapy was associated with a significant reduction in target lesion revascularization (OR 0.52, 95% CI 0.38-0.70, p<0.001), with no difference in mortality (OR 0.77, 95% CI 0.48-1.24, p=0.29) or stent thrombosis (OR 1.0, 95% CI 0.44-2.28, p=0.99). There was no significant difference in bleeding episodes between the two groups (OR 1.01, 95% CI 0.60-1.70, p=0.98).

Conclusions: Cilostazol in addition to dual antiplatelet therapy appears to be effective in reducing the risk of restenosis and repeat revascularization after PCI without any significant benefits for mortality or stent thrombosis.

![Graphic][1]  [1]: /embed/inline-graphic-1.gif
Abstract P1-12-07: Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years
Authors: Eunshin Lee, Han-Byoel Lee, Young Joon Kang, Yun-Gyoung Kim, Tae-kyung Yoo, Jongjin Kim, Min Kyoon Kim, Hyeong-Gon Moon, Dong-Young Noh, Wonshik Han
Journal: Cancer Research (2015)

Abstract Background Treatment with tamoxifen (TMX) reduces the recurrence rate and increase overall survival in patients with hormone receptor positive breast cancer. Up to now, 5-year TMX therapy is generally accepted, but it is demonstrated that the rate of late recurrence after 5 years is considerably higher in hormone receptor positive type than in other subtype. Several clinical trials such as ATLAS and aTTom showed the benefit of continuing tamoxifen up to 10 years instead of stopping at 5 years without increasing mortality due to the effect of extended tamoxifen medication. Method We collected data of 1633 hormone receptor positive breast cancer patients who received surgery at Seoul National University Hospital from 1997 to 2007, and had completed 5-year TMX therapy with no recurrence within 5 years after diagnosis. Mean age of the patients was 43.3, and the patients have estrogen receptor or progesterone receptor. We included from the stage I to stage IV patients underwent curative surgery and received adequate adjuvant therapy such as chemotherapy or radiation therapy after surgery. We excluded the cases treated aromatase inhibitor (AI) or switched to AI. Result Among these patients, recurrences after 5 years of TMX therapy were found in 93 patients (late recurrence group). Local recurrences and distant metastases were found in 43 and 50 patients, respectively. Electronic medical records were retrospectively reviewed for clinicopathological factors. When comparing between patients with no recurrence and patients with late recurrence, p53 and HER-2 expression were significantly related to late recurrence (p=0.01, p&amp;lt;0.001 respectively). Also when subgroup analysis was done for distant metastasis of late recurrence group, distant metastasis was significantly associated with HER-2 expression and high nuclear grade (p=0.005, p=0.006 respectively). There are no relation between late recurrence and age, stage and ki-67. Conclusion our data shows that p53 and HER-2 expression is associated to late recurrence and especially HER-2 expression is related to distant metastasis after completing TMX for 5 years. On the basis of the result of large clinical trials, extending TMX therapy significantly reduces recurrence rate and increase survival. Our result support continuing TMX in patients with HER-2 expression and high nuclear grade is considerable after 5 years of TMX medication. Citation Format: Eunshin Lee, Han-Byoel Lee, Young Joon Kang, Yun-Gyoung Kim, Tae-kyung Yoo, Jongjin Kim, Min Kyoon Kim, Hyeong-Gon Moon, Dong-Young Noh, Wonshik Han. Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-12-07.
Downregulation of MiR-449a Is Essential for the Survival of EVI1 Positive Leukemic Cells through Modulation of NOTCH1 and BCL2.
Authors: An De Weer, Pieter Mestdagh, Katleen De Preter, Joni Van der Meulen, Pieter Van Vlierberghe, Tom Van Maerken, Nadine Van Roy, Marta Jeison, Isaac Yaniv, Barbara Cauwelier, Lucien Noens, Hélène-Antoine Poirel, Peter Vandenberghe, Frédéric Lambert, Anne De Paepe, Torsten Konrad, Rotraud Wieser, Maria García Sánchez, Maria Odero, Bruno Verhasselt, Jan Philippé, Jo Vandesompele, Nicole Dastugue, Bruce Poppe, Frank Speleman
Journal: Blood (2009)
Abstract 18319: Cardiac Services for Care of Suspected Acute Coronary Syndromes in Australia and New Zealand Hospitals
Authors: Isuru Ranasinghe, Carolyn Astley, Bernadette Aliprandi-Costa, Derek Chew, Christopher J Ellis, Christopher J Hammett, Tom G Briffa, Tegwen E Howell, Karen J Lintern, Hella Parker, Bridie Carr, Greg D Gamble, Rosanna Tavella, Julie Redfern, John French, David Brieger
Journal: Circulation (2013)

Background: Population-wide assessment of cardiac services recommended for optimal acute coronary syndromes (ACS) care has not been previously performed. We assessed the availability of ACS services among hospitals in Australia and New Zealand. Method: Services recommended for optimal ACS outcomes were identified from ACS guidelines and clinical consensus, and were collected from hospitals using a structured questionnaire. Thirty services reflecting acute care, investigations and procedures, management of complications, and preventative services were included. Data on consecutive ACS admissions over 2 weeks was simultaneously collected. Results: Of the 433 acute hospitals in both countries, 273(63%) provided service characteristics and 243(89%) provided patient data (n=2287 ACS patients). Figure shows the availability of selected services. Among hospitals, an emergency physician was available in 50%, cardiology consultation was available acutely in 35% and 22% provided primary PCI. Most investigations/procedures were available in &lt;50% of hospitals except exercise stress testing (58%) and echocardiography (56%). A CCU was present in 52%, 44% provided an inpatient cardiology service, 52% provided a follow-up clinic and &lt;40% provided an outpatient heart failure program or a readmissions reduction program. Service availability varied markedly among hospitals (median 14 services,IQR 7-30). Among hospitals that collected patient data, 25% of all patients presented to hospitals with &lt;50%(15/30) of services and only 40% were cared at hospitals with &gt;80%(24/30) services available. Service availability was not correlated with in-hospital outcomes although the study lacked sufficient power. Conclusion: The availability of cardiac services for optimal ACS care varies widely in Australian and New Zealand hospitals. Such inequalities resulting from uncoordinated dissemination of healthcare resources may contribute to variations in ACS outcomes
Prevention of Atrial Fibrillation Recurrence With Corticosteroids After Radiofrequency Catheter Ablation
Authors: Takashi Koyama, Hiroshi Tada, Yukio Sekiguchi, Takanori Arimoto, Hiro Yamasaki, Kenji Kuroki, Takeshi Machino, Kazuko Tajiri, Xu Dong Zhu, Miyako Kanemoto-Igarashi, Aiko Sugiyasu, Keisuke Kuga, Yoshio Nakata, Kazutaka Aonuma
Journal: Journal of the American College of Cardiology (2010)
Abstract 14914: Sudden Cardiac Arrest Manifesting With Shockable vs. Non-Shockable Rhythms
Authors: Carmen Teodorescu, Audrey Uy-Evanado, Kyndaron Reinier, Ronald Mariani, Karen Gunson, Jonathan Jui, Sumeet S Chugh
Journal: Circulation (2013)

Introduction: Sudden cardiac arrest (SCA) presenting with non-shockable rhythms (pulseless electrical activity or asystole) has a significantly higher mortality than shockable rhythms (ventricular ...
Breathless
Authors: Michael C. Gavin, Danielle Morse, Ann H. Partridge, Bruce D. Levy, Joseph Loscalzo
Journal: New England Journal of Medicine (2012)

A 50-year-old woman presented with fatigue and shortness of breath. Dyspnea after moderate exertion had developed gradually, along with profound malaise and a nonproductive cough. In the 48 hours before admission, her shortness of breath had worsened.
Abstract MP006: Plasma and Erythrocyte Biomarkers of Dairy Fat Intake and Risk of Coronary Heart Disease in Men
Authors: Vasanti S Malik, Hongyu Wu, Frank B Hu, Qi Sun
Journal: Circulation (2012)

Introduction: Intake of dairy products have been postulated to be associated with risk of coronary heart disease (CHD) because of their high saturated fat content, however studies examining this relation have yielded inconsistent results. Given the widespread consumption of dairy products, further evaluation of this controversial topic using biological markers of dairy fat intake is warranted. Objective: To evaluate plasma and erythrocyte odd chain fatty acids and certain trans isomers as biomarkers of dairy fat intake and assess their relation to risk of CHD in US men. Methods: We conducted a case-control study nested within the Health Professionals Follow-up study among 18,140 men who provided blood samples between 1993 and 1994. From baseline to 2008, four hundred and fifty-nine cases of CHD were ascertained and matched with 879 controls for age, smoking, fasting status and date of blood draw. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (95% CI) for CHD. Results: Among controls, we identified certain fatty acids that were significantly correlated with dairy fat intake: the correlation coefficients between average dairy fat intake in 1986–1994 and 15:0, 17:0, 19:0, 23:0 and trans 16:1n−7 were 0.27, 0.24, 0.10, 0.22 and 0.31 respectively for plasma and 0.25, 0.21, 0.05, 0.21 and 0.30 respectively for erythrocytes. In multivariate analyses controlling for matching factors and other diet and lifestyle risk factors, men with higher plasma concentrations of 15:0 had a significantly greater risk of CHD (RR: 1.61, 95% CI: 1.07, 2.43, p trend: 0.02, comparing extreme tertiles of plasma 15:0). Associations with other biomarkers were not significant in multivariate analyses and associations were generally weaker in erythrocytes. Conclusions: These data confirm that certain odd chain fatty acids and trans 16:1n−7 may be used as biomarkers of dairy fat intake and suggest that a high intake of dairy fat is associated with an elevated risk of CHD.
Too high a pedestal
Authors: Jeffrey K Aronson
Journal: BMJ (2008)

Freemantle and Irs are wrong to say that only properly randomised trials can provide truly reliable evidence on adverse events, just as these are the only source of convincing data on drug efficacy.1 Harms due to drugs differ from benefits in several ways: they are multifarious and affect fewer individuals, some of whom may have particular susceptibilities. Harms often cannot …
Abstract 705: The Difference in Left Ventricular Twisting Behavior Between Patients With Hypertensive Heart Disease and Hypertrophic Cardiomyopathy
Authors: Kazuhisa Nishimura, Hideki Okayama, Makoto Saito, Katsuji Inoue, Toyofumi Yoshii, Go Hiasa, Takumi Sumimoto, Jun Suzuki, Akiyoshi Ogimoto, Tomoaki Ohtsuka, Junichi Funada, jitsuo Higaki
Journal: Circulation (2008)

(Background) Left ventricular (LV) untwisting behavior is a novel index of LV diastolic function since it is a powerful determinant of LV diastolic suction. The LV of patients with hypertrophic cardiomyopathy (HCM) and hypertensive heart disease (HHD) has diastolic dysfunction despite normal systolic function. However, the role of untwisting behavior in HCM and HHD in the pathophysiology of diastolic dysfunction is unknown. The aim of this study was to investigate the difference of LV twisting behavior between patients with HCM and HHD. (Methods) Forty-four patients with HCM (mean age, 63+/−15 y, 34 males), 30 patients with HHD (mean age, 62+/−12 y, 20 males), and 20 age and sex-matched control subjects were evaluated. After a standard echocardiographic examination, LV twist and twisting velocity profiles from apical and basal short-axis images were analyzed using two-dimensional speckle tracking imaging. All temporal parameters were normalized by R-R intervals. (Results) LV diastolic and systolic dimensions, and ejection fraction were not significantly different among the groups. LV mass index and early diastolic mitral annular velocity were not significantly different between the HCM and HHD groups. The peak torsion in the HCM and HHD groups was significantly greater than that in the control group (Table ). The peak untwisting velocity in the HCM group was comparable to that in the control group. However, when the peak untwisting velocity was corrected by peak torsion, the value in the HCM group was significantly decreased compared with that in the HHD and control groups. The time to peak untwisting velocity from aortic valve closure in the HCM group was significantly longer than that in the HHD and control groups. (Conclusion) These results suggest that enhanced peak torsion in HCM might compensate for untwisting behavior, but this mechanism fails to fully compensate for untwisting behavior compared with HHD. Left ventricular twisting behavior